title: Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy.
abstract: BACKGROUND
  Circulating oxidized LDL (ox-LDL) is associated with clinical manifestations of atherosclerosis. The aim of the study was to investigate the concentrations of ox-LDL in HIV-infected patients under antiretroviral therapy with (HIV-LD) or without (HIV-nLD) HIV-related lipodystrophy.
  
  
  METHODS
  A total of 44 HIV-infected men were enrolled in the study. Half of them had HIV-LD. The control group included 12 age- and body mass index (BMI)-matched HIV-uninfected men. Ox-LDL concentration and C-reactive protein level were determined. Insulin sensitivity was measured using the homeostasis model assessment (HOMA-IR). LD was assessed by using a validated score calculated from clinical and biological data.
  
  
  RESULTS
  HIV-infected patients had significantly higher ox-LDL concentrations when compared to HIV-negative controls (0.8 +/- 0.3 mg/dL vs. 0.60 +/- 0.1 mg/dL; p = .007). HIV-LD patients had significantly higher ox-LDL concentrations than HIV-nLD patients (0.91 +/- 0.38 and 0.69 +/- 0.16; p = .04). In HIV-LD patients, current therapy with protease inhibitors (PIs); duration of PI therapy; HOMA-IR; and time exposure to stavudine, efavirenz, ritonavir, saquinavir, and amprenavir were significantly higher than in HIV-nLD patients. In multivariate analysis, time exposures to stavudine and ox-LDL concentration were independently related to lipodystrophy.
  
  
  CONCLUSIONS
  The high concentration of ox-LDL was found in HIV-infected patients under antiretroviral therapy, especially in those with lipodystrophy.
authors.affiliation: Division of Infectious Diseases, University Hospital, Dijon, France. michel.duong@chu-dijon.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Duong
authors.forename: Jean Michel
authors.initials: JM
authors.lastname: Petit
authors.forename: Benoit
authors.initials: B
authors.lastname: Martha
authors.forename: Françoise
authors.initials: F
authors.lastname: Galland
authors.forename: Lionel
authors.initials: L
authors.lastname: Piroth
authors.forename: Anne
authors.initials: A
authors.lastname: Walldner
authors.forename: Michèle
authors.initials: M
authors.lastname: Grappin
authors.forename: Marielle
authors.initials: M
authors.lastname: Buisson
authors.forename: Laurence
authors.initials: L
authors.lastname: Duvillard
authors.forename: Pascal
authors.initials: P
authors.lastname: Chavanet
authors.forename: Henri
authors.initials: H
authors.lastname: Portier
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1; D039682:HIV-Associated Lipodystrophy Syndrome / Q000097:blood / Q000188:drug therapy; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein